Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
AbbVie
Modality
Small molecule
Development Phase
Phase 1/2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02709889CT.gov Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | — | Terminated | — | — | — |
NCT00923247CT.gov A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Medullary Thyroid Gland Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dexasone (this asset) | AbbVie | P1/2 | CCC · 48 |
| Tarlatamab | University of Arizona | P2 | B |
| Cabozantinib | National Cancer Institute (NCI) | P2 | B |
| Selpercatinib | Eli Lilly and Company | P2 | B |
| Oxodotreotide | M.D. Anderson Cancer Center | P2 | CCC |
| Pralsetinib, Trans- | Hoffmann-La Roche | P1/2 | CCC |
| Everolimus | National Cancer Institute (NCI) | P1 | CCC |
| ty-1091 | TYK Medicines, Inc | P1/2 | CCC |
| Bortezomib | National Cancer Institute (NCI) | P1/2 | CCC |
+26 more in the Medullary Thyroid Gland Carcinoma cohort
Other indications for Dexasone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Chemotherapy-Induced Toxicity | — | P4 | A · 82 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 79 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 78 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dexasone in Medullary Thyroid Gland Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dexasone-medullary-thyroid-gland-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →